Inventor · disambiguated record
Pierre Coulie
Also filed as: COULIE PIERRE · COULIE PIERRE G
53 granted patents·5 pending applications·729 citations·filing 1990–2020
98Inventor score
Top patents by PatentIndex Score
58 records- 0194US5830753AIsolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.LUDWIG INST CANCER RES·Filed 1994·Granted Nov 3, 1998·82 cites·14 claims
- 0293US10000572B2Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibodyLUDWIG INST FOR CANCER RES LTD·Filed 2014·Granted Jun 19, 2018·22 cites·8 claims
- 0391US5571711AIsolated nucleic acid molecules coding for BAGE tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1993·Granted Nov 5, 1996·69 cites·11 claims
- 0487US10793627B2GARP-TGF-β 1 IGG antibodiesARGENX BVBA·Filed 2019·Granted Oct 6, 2020·2 cites·1 claims
- 0586US6130052ALeukemia associated genesLUDWIG INST CANCER RES·Filed 1998·Granted Oct 10, 2000·89 cites·8 claims
- 0682US10875914B2Nucleic acids encoding GARP-TGF-beta 1 antibodiesARGENX BVBA·Filed 2019·Granted Dec 29, 2020·1 cites·18 claims
- 0781US10822424B2Method of screening for anti-GARP antibodiesUNIV CATHOLIQUE LOUVAIN·Filed 2019·Granted Nov 3, 2020·1 cites·12 claims
- 0881US6022692AMethod for screening for possible presence of cancerLUDWIG INST CANCER RES·Filed 1998·Granted Feb 8, 2000·38 cites·7 claims
- 0979US6669946B2Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2001·Granted Dec 30, 2003·5 cites·1 claims
- 1079US5585461AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 17, 1996·39 cites·4 claims
- 1179US5487974AMethod for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cellsLUDWIG INST CANCER RES·Filed 1993·Granted Jan 30, 1996·59 cites·6 claims
- 1278US10479829B2GARP-TGF-beta 1 antibodiesARGENX BVBA·Filed 2018·Granted Nov 19, 2019·1 cites·16 claims
- 1376US7547517B2MAGE-C2 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2003·Granted Jun 16, 2009·3 cites·6 claims
- 1476US5591430AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jan 7, 1997·35 cites·6 claims
- 1573US5747271AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1996·Granted May 5, 1998·39 cites·2 claims
- 1672US5116951ASubstantially pure interleukin-9 receptor and uses thereofLUDWIG INST CANCER RES·Filed 1990·Granted May 26, 1992·34 cites·4 claims
- 1771US6497879B1Immunogenic compositions of tumor rejection antigen precursor MAGE-10 and an adjuvantLUDWIG INST CANCER RES·Filed 2000·Granted Dec 24, 2002·1 cites·3 claims
- 1870US11230603B2Anti-GARP proteinLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Jan 25, 2022·0 cites·15 claims
- 1970US6682731B1Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 moleculesLUDWIG INST CANCER RES·Filed 2000·Granted Jan 27, 2004·3 cites·2 claims
- 2069US8143011B2MAGE-C2 antigenic peptides and uses thereofMA WENBIN·Filed 2011·Granted Mar 27, 2012·1 cites·6 claims
- 2169US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 2269US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
- 2367US5851523AIsolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 22, 1998·20 cites·7 claims
- 2467US2021324061A1Garp-tgf-beta antibodiesARGENX BVBA·Filed 2020·Application pending·0 cites
- 2566US10604579B2Antibody against a complex between human GARP and latent TGF-βLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 31, 2020·0 cites·5 claims
- 2666US5530096AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jun 25, 1996·22 cites·1 claims
- 2762US5589334AIsolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 31, 1996·23 cites·14 claims
- 2862US5180678AUses of substantially pure interleukin-9 receptorLUDWIG INST CANCER RES·Filed 1992·Granted Jan 19, 1993·22 cites·6 claims
- 2961US6271019B1Leukemia associated genesLUDWIG INST CANCER RES·Filed 1999·Granted Aug 7, 2001·13 cites·19 claims
- 3058US6770456B1Endogenous retrovirus tumor associated nucleic acids and antigensLUDWIG INST CANCER RES·Filed 1998·Granted Aug 3, 2004·14 cites·18 claims
- 3157US2009233315A1MAGE-C2 antigenic peptides and uses thereforMA WENBIN·Filed 2009·Application pending·0 cites
- 3256US2003138854A1Method for determining BAGE expressionFiled 2002·Application pending·0 cites
- 3355US2016251438A1Anti-garp protein and uses thereofARGEN-X N V·Filed 2016·Application pending·0 cites
- 3453US5879892ALeukemia associated genesLUDWIG INST CANCER RES·Filed 1997·Granted Mar 9, 1999·10 cites·9 claims
- 3552US6339149B1Isolated nucleic acid molecules which encode tumor rejection antigens found in dageLUDWIG INST CANCER RES·Filed 1998·Granted Jan 15, 2002·7 cites·5 claims
- 3650US2003158388A1MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereofFiled 2002·Application pending·0 cites
- 3749US6387698B1MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted May 14, 2002·0 cites·3 claims
- 3848US8492342B2Preprocalcitonin antigen T epitopesEL HAGE FATEN·Filed 2008·Granted Jul 23, 2013·0 cites·12 claims
- 3948US5846826AIsolated cytolytic T cell line specific to complexes of HLA-B44 molecules and specific nonapeptidesLUDWIG INST CANCER RES·Filed 1996·Granted Dec 8, 1998·7 cites·1 claims
- 4046US6245333B1Isolated protein processed to peptides which form complexes with HLA moleculesLUDWIG INST CANCER RES·Filed 1998·Granted Jun 12, 2001·3 cites·2 claims
- 4146US6174692B1MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Jan 16, 2001·6 cites·2 claims
- 4246US6013765AIsolated tumor rejection antigens derived from DAGE tumor rejection antigen precusorLUDWIG INST CANCER RES·Filed 1995·Granted Jan 11, 2000·2 cites·3 claims
- 4346US5908778AMage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Jun 1, 1999·3 cites·7 claims
- 4444US6465184B1Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Oct 15, 2002·2 cites·7 claims
- 4543US6680056B1Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of hla-cw 1601/mage-1 derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2000·Granted Jan 20, 2004·0 cites·3 claims
- 4643US6297050B1Methods for treating subject with DAGE derived peptidesLUDWIG INST CANCER RES·Filed 1999·Granted Oct 2, 2001·6 cites·19 claims
- 4741US5843688AIsolated tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Dec 1, 1998·2 cites·3 claims
- 4839US6638512B1Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigensLUDWIG INST CANCER RES·Filed 1999·Granted Oct 28, 2003·1 cites·21 claims
- 4937US5997870AIsolated peptides which bind to HLA-B44 MoleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 7, 1999·2 cites·2 claims
- 5036US6110694AMethods for determining complexes of tumor rejection antigens and HLA-Cw*160/moleculesLUDWIG INST CANCER RES·Filed 1998·Granted Aug 29, 2000·2 cites·5 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pierre Coulie files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →